Article
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Frontiers in Pharmacology
(2021)
Abstract
Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis of MM. Thus, inhibition of the Mcl-1 protein considered as a therapeutic strategy to kill the myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. This review presents the critical role of Mcl-1 in the progression of MM, the most prominent BH3 mimetic and semi-BH3 mimetic that selectively inhibit Mcl-1, and could be used as single agent or combined with existing therapies.
Disciplines
Publication Date
July 19, 2021
DOI
10.3389/FPHAR.2021.699629
Citation Information
Omar S. Al-Odat, Max von Suskil, Robert J. Chitren, Weam O. Elbezanti, et al.. "Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma" Frontiers in Pharmacology Vol. 12 (2021) p. 699629 Available at: http://works.bepress.com/subash-jonnalagadda/15/
Creative Commons license
![Creative Commons License](https://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons CC_BY International License.